Diligence memo · auto-generated · as of July 3, 2026
Aktis Oncology, Inc.
Aktis Oncology, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Aktis Oncology, Inc. operates in Biotechnology, based in BOSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aktis Oncology, Inc. has raised $175M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $175M on 2024-09-20.
Most recent recorded round closed around 2024-09-20.
Valuation (modeled)modeled
Provath models Aktis Oncology, Inc. at approximately $1.8B (range $793M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.89× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era. Within the normal band (89% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 21 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotechnology peers (4293 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.